A Phase 3 interventional study of Albumin-Bound Paclitaxel and Carboplatin in Cervical Cancer, Neoadjuvant Chemotherapy and Bulky Neoplasm, sponsored by Sun Yat-sen University. Recruiting at 1 site in China. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-05-10.
Sponsored by Sun Yat-sen University · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing carboplatin in Uterine Cervical Neoplasms — 5 open to participants now, 6 under way, 5 of them phase 3. Carboplatin · Uterine Cervical Neoplasms.
Among the 24 studies testing carboplatin in Uterine Cervical Neoplasms, this one is the 6th largest by planned enrollment, is one of 2 that started in 2022, is one of 8 in phase 3, and was the 23rd registered.
2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.
Browse Uterine Cervical Neoplasms studies →5 of the 24 studies testing carboplatin in Uterine Cervical Neoplasms are open now, in 5 countries. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States, Puerto Rico
Ages 18+ · Women only
University Hospital, Toulouse · Sites in France
Ages 18+ · Women only
University Health Network, Toronto · Sites in United States, Canada
Ages 18–40 · Women only
Charite University, Berlin, Germany
Ages 18+ · Women only
By country, each count listing its studies:
Carboplatin: first FDA approval 1989 (PARAPLATIN). What it is approved for, and how studies give it, is on its page →
Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.
This study: 18 Years to 70 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 12 · Phase 3 8
First in 2001; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 280 is above the median of 100 across 1,740 interventional studies indexed under Uterine Cervical Neoplasms.
Median enrollment 59 across the 24 interventional studies. Of the 12 that completed or were terminated, 1 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 24 have an industry lead sponsor. The 10 most frequent:
Sun Yat-sen University is the lead sponsor of 1,695 studies on the registry; 622 are open to participants now.
18 studies in Uterine Cervical Neoplasms by Sun Yat-sen University: 7 open now, 9 under way, 3 of them phase 3. Of 4 finished, 0 (0%) have results posted.
Among the 18 studies in Uterine Cervical Neoplasms by Sun Yat-sen University, this one is the 6th largest by planned enrollment of the 17 interventional ones that give a count, is the only one that started in 2022, is one of 6 in phase 3, and was the 14th registered.
Sun Yat-sen University’s Uterine Cervical Neoplasms studies by the year they started, since 2008.
1 of the studies testing carboplatin in Uterine Cervical Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04016389University Health Network, TorontoFIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 24 studies testing carboplatin in Uterine Cervical Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sun Yat-sen University’s 18 in Uterine Cervical Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Evaluate the efficacy and safety of neoadjuvant chemotherapy (NAC) with albumin-bound paclitaxel and carboplatin followed by chemoradiation therapy (CRT) for stage IIIC cervical cancer patients with carcinoma >4 cm in greatest dimension and/or lymph node >2cm in short axis.
in this phase III tiral , stage IIIC cervical cancer patients with carcinoma >4 cm in greatest dimension and/or lymph node >2cm in short axis will be randomly assigned to two circles of NAC with albumin-bound paclitaxel and carboplatin followed by standard CRT with weekly cisplatin plus pelvic radiotherapy or to standard CRT alone.
The primary end point was 3-year progression-free survival (PFS). Secondary end points were response rate, 3-year locoregional control, 3-year overall survival (OS), safety, and quality of life.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
two circles of NAC with albumin-bound paclitaxel and carboplatin followed by standard chemoradiation with weekly cisplatin plus pelvic radiation
Drug: Albumin-Bound Paclitaxel · Drug: Carboplatin
standard chemoradiation with weekly cispatin plus pelvic radiation
260mg/m2 q3w \*2 circles
AUC 5-6 q3w \* 2 circles
3-year progression-free survival ratio
the time from study randomization to 3 years, the ratio for patients without disease progression nor death.
Time frame: up to 3 years
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2022 (actual). Primary completion is estimated for Mar 2024, 24 months after the start.
Of 53 non-industry phase 3 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 80 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 107. This study's planned 24 months is below that.
Counting every sponsor, half of 99 studies reached it within 55 months; a quarter within 24 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Albumin-Bound Paclitaxel · Carboplatin